

Vaccine Fact Sheet: HPV9

Topic	GARDASIL® 9
Manufacturer	Merck Prescribing Info (FDA)
Protects Against	Human papillomavirus types 6, 11, 16, 18, 31, 33, 45, 52 & 58, which can cause cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers as well as genital warts
Approved Ages	Ages 9–45 years
Funding Source	VFC, VFA, LHD 317
Routine Schedule	<ul style="list-style-type: none"> • 2 doses for persons initiating vaccination at age 9–14 years except immunocompromised persons • 3 doses for persons initiating vaccination at age 15 or older and immunocompromised persons initiating vaccination at age 9 or older
Minimum Intervals	2-dose series: 5 months between doses 3-dose series: <ul style="list-style-type: none"> • 4 weeks between doses 1 & 2 • 12 weeks between doses 2 & 3 • 5 months between doses 1 & 3
Administration	Intramuscular (IM) injection
Packaging	Vaccine packaged as 10 single-dose 0.5mL prefilled syringes
Storage	Refrigerate between 36°F and 46°F (2°C and 8°C) Protect Vaccine from Light - Do Not Freeze
Recommendations	CDC's MMWR (2019)
Program Letter	VFC Letter (PDF)
Billing Codes	CPT code for vaccine: 90651 CPT code for administration*: 90460 Medi-Cal Fee-For-Service (FFS) administration: 90651 with modifiers –SK (high- risk) and –SL (VFC) ICD-10-CM code (encounter for immunization): Z23 Coding for Vaccine Administration (PDF)
Comments	Licensed in 2014

Refer to [Vaccine Fact Sheets](#) (EZIZ.org/Resources/VaccineFactSheets).